Volume 22, Number 6—June 2016
Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection
To the Editor: Recent advances in the understanding of antimycobacterial immune response have led to descriptions of predisposing conditions to dissemination of nontuberculous mycobacteria (NTM) infection. The interferon- γ (IFN-γ)/interleukin-12 (IL-12) axis is a critical pathway for intracellular killing of mycobacteria (Technical Appendix[PDF - 294 KB - 6 pages] Figure) (1).We report a case of disseminated NTM infection in a woman from Laos who showed IFN-γ autoantibodies. We also conducted a literature review to review similar cases.
A previously healthy 50-year-old woman from Laos was referred to Hospices Civils de Lyon, France, for fever and generalized lymphadenopathies; pathological examination revealed a nonnecrotizing granuloma. Culture yieldedMycobacterium fortuitum. After a 3-month azithromycin/ciprofloxacin regimen, symptoms resolved. A few months later, a computed tomography scan showed persistence of enlarged mediastinal lymph nodes; biopsy disclosed nonspecific sinus histiocytosis. Mycobacterial cultures were negative. One month later, the patient reported intense dorsal spine pain. She was diagnosed with multifocal vertebral osteomyelitis, and tissue specimens tested positive for M. intracellulare. Azithromycin/ciprofloxacin was prescribed again. At 6 months, lesions worsened, and epidural abscess led to spinal cord compression, requiring decompressive laminectomy. Postoperative cultures were positive for M. intracellulare. Treatment was changed to azithromycin, rifabutin, ethambutol, and amikacin for 2 weeks, then rifabutin and moxifloxacin, which led to clinical improvement.
The patient experienced 2 episodes of thoracic herpes zoster concomitantly to each episode of illness. The recurrent NTM infection led us to investigate her immune status. Results of standard immunologic tests (leukocyte, serum level of immunoglobulin isotypes, and T-, B-, and NK0cell counts) and in vitro T-cell proliferation were normal; HIV testing was negative. Given its critical role in Mycobacteria clearance by host cells, we used IFN-γ whole-blood activation to investigate further. IFN-γ plasma level was undetectable, excluding complete forms of IFN-γ R1/R2. IL-12 p40 subunit plasmatic level was decreased, but the IL-12 receptor was present and functional. In addition, both BCG and IL-12 stimulations failed to trigger IFN-γ production. Ultimately, the detection of IFN-γ autoantibodies in high levels explained these abnormalities. Antimycobacterial treatment was continued for 2 years, then changed to azithromycin suppressive therapy; IFN-γ autoantibodies remained positive at the time of this report, 2 years after azithromycin initiation.
We reviewed the literature and found 63 other cases of IFN-γ autoantibody-related NTM infection with sufficient detail to provide clinically relevant material for optimizing disease management (Table; Technical Appendix[PDF - 294 KB - 6 pages]). These cases overwhelmingly occurred among Asian populations (92.2%) (2). Disease incidence may be underestimated, as suggested by large studies describing Asian patients with disseminated NTM infection without evidence of impaired immunity but for whom the IL-12/IFN-γ axis was not investigated (3). This acquired autoantibodies–mediated immunodeficiency is more frequent among women, in whom the disease typically manifests in the second half of adult life (median 48 [IQR 44.8–60.0] years of age). Reported female:male sex ratios are 23/36 in Asian-born (n = 59) and 4/1 in non-Asian (n = 5) case-patients, respectively. Mechanism of the disease is briefly discussed in the Technical Appendix[PDF - 294 KB - 6 pages].
M. avium complex predominated in the literature review, accounting for 40.4% of cases, followed by M. abscessus (31.6%) and M. fortuitum (12.3%). Infections were mostly multifocal, affecting lymph nodes (n = 51, 79.7%), osteoarticular tissue (n = 37, 57.8%), lungs (n = 30, 46.9%), and skin and/or soft tissues (n = 24, 37.5%). Aside from NTM infections, other opportunistic infections were reported in 39 (75.0%) patients, mostly Herpesviridaereactivations (44.2%) and Salmonella infections (25.0%) (3–6).
Specific treatment for IFN-γ autoantibodies–associated NTM infection is not codified and required prolonged, multiple-drug regimens. The median treatment duration for the studies we reviewed was 31 (IQR 22.8–60.0) months. In some studies, clinicians used IFN-γ administration (5 patients, 1 of whom was cured), but treatment likely was invalidated by the autoimmune-driven inhibitory activity (5,2,7). Other strategies included intravenous immunoglobulin (n = 2), plasmapheresis (n = 2), and cyclophosphamide (n = 1) (7–9). The use of rituximab, a chimeric anti-CD20 monoclonal antibody targeting B-cells, has been recently associated with clinical response and decrease in IFN-γ autoantibody levels as well as neutralizing ability (6,7).
Final outcome was available for 56 patients who completed the intensive treatment phase; 21 (37.5%) were declared cured. Six (10.7%) patients died, and 29 (51.8%) had persistent or relapsing infections. At the time of this report, additional patients were still being treated and showed improvement of symptoms. Despite this high rate of failure, long-term antimicrobial drug suppressive therapy has rarely been proposed as a causal factor. The origin of the case we report was related to the use of azithromycin suppressive therapy, similarly to disseminated NTM disease prophylaxis in HIV-infected patients before the era of highly active antiretroviral therapies (10), assuming the risk/benefit balance including the possibility of NTM macrolide-resistant strain selection.
IFN-γ autoantibodies are evidence of acquired immunodeficiency that should be considered in cases of unexplained disseminated NTM infections in Asian-born persons. Use of immunomodulation strategies is still debated, and long-term suppressive treatment should be considered for persisting high levels of neutralizing antibodies.
We thank Lyon tuberculosis study group members F. Ader, F. Biron, A. Boibieux, A. Bouaziz, E. Braun, G. Catho, N. Charhon, C. Chidiac, W. Chumbi-Flores, S. Couraud, G. Devouassoux, O. Dumitrescu, S. Ernesto, T. Ferry, D. Floret, N. Freymond, S. Gardes, S. Gerbier-Colomban, Y. Gillet, S. Goutelle, J. Grando, R. Grima, L. Hees, J. Karsenty, L. Kiakouama-Maleka, G. Lina, J. M. Maury, P. Miailhes, P. Nesme, T. Perpoint, E. Perrot, A. S. Ronnaux-Baron, S. Roux, J. Saison, A. Senechal, P. J. Souquet, H. Thai Van, F. Tronc, F. Valour, and P. Vanhems for choosing research field priorities and editing one another’s reports article for this manuscript.
- Wu U-I, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15:968–80. DOIPubMed
- Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J Clin Invest. 2005;115:2480–8. DOIPubMed
- Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367:725–34. DOIPubMed
- Chi C-Y, Chu C-C, Liu J-P, Lin C-H, Ho M-W, Lo W-J, Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood.2013;121:1357–66. DOIPubMed
- Döffinger R, Helbert MR, Barcenas-Morales G, Yang K, Dupuis S, Ceron-Gutierrez L, Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2004;38:e10–4. DOIPubMed
- Czaja CA, Merkel PA, Chan ED, Lenz LL, Wolf ML, Alam R, Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody. Clin Infect Dis. 2014;58:e115–8. DOIPubMed
- Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012;119:3933–9. DOIPubMed
- Koya T, Tsubata C, Kagamu H, Koyama K, Hayashi M, Kuwabara K, Anti-interferon-gamma autoantibody in a patient with disseminatedMycobacterium avium complex. J Infect Chemother. 2009;15:118–22. DOIPubMed
- Baerlecken N, Jacobs R, Stoll M, Schmidt RE, Witte T. Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-gamma autoantibody. Clin Infect Dis. 2009;49:e76–8. DOIPubMed
- Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335:392–8. DOIPubMed
Suggested citation for this article: Valour F, Perpoint T, Sénéchal A, Kong XF, Bustamante J, Ferry T, et al. Interferon-γ autoantibodies as predisposing factor for nontuberculous mycobacterial infection [letter]. Emerg Infect Dis. 2016 Jun [date cited]. http://dx.doi.org/10.3201/eid2206.151860
No hay comentarios:
Publicar un comentario